There's a scientific breakthrough in your medicine cabinet. But how did it get there?
At a time when medicines are helping us all live longer and healthier lives, this podcast will explore where these taken-for-granted miracles come from, how many of them almost never happened, where the life science ecosystem is taking us next, and most importantly, what it means for patients.
From chance meetings that led to new ideas, to risky investments that never pay off, hear from the people behind today's and tomorrow's treatments, vaccines, technologies, devices, and yes, cures.
In this golden age of health discovery and innovation fueled by record breaking investment in the life sciences, we'll bring guests who really understand what it means to be Making Medicine.
All content for Making Medicine is the property of Incubate Coalition and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
There's a scientific breakthrough in your medicine cabinet. But how did it get there?
At a time when medicines are helping us all live longer and healthier lives, this podcast will explore where these taken-for-granted miracles come from, how many of them almost never happened, where the life science ecosystem is taking us next, and most importantly, what it means for patients.
From chance meetings that led to new ideas, to risky investments that never pay off, hear from the people behind today's and tomorrow's treatments, vaccines, technologies, devices, and yes, cures.
In this golden age of health discovery and innovation fueled by record breaking investment in the life sciences, we'll bring guests who really understand what it means to be Making Medicine.
In this week’s episode, John Stanford breaks down Day 15 of the federal shutdown’s impact on health agencies, major pullbacks in cell & gene therapy, and the White House’s latest MFN-style deal with AstraZeneca following Pfizer. We’re joined by Incubate’s Policy Director John Guy to explain how “BIOSECURE” found new life inside the Senate’s NDAA and what that means for biopharma. We also cover investment trends, workforce concerns, and the new DoD Biotech Management Office mandate. Stick around to the end for how all this could reshape U.S. innovation and supply chains.
How will MFN-style deals affect launch strategy and U.S. pricing? Do recent exits by Novo Nordisk and Takeda change your outlook on cell & gene therapy? What’s your biggest question about BIOSECURE's due-process path and NDAA timing?
DOD 1260H List: https://media.defense.gov/2025/Jan/07/2003625471/-1/-1/1/ENTITIES-IDENTIFIED-AS-CHINESE-MILITARY-COMPANIES-OPERATING-IN-THE-UNITED-STATES.PDF
If you're new to the Making Medicine Podcast, we're happy you're here! Follow us for more: https://x.com/MakingMedPod https://www.instagram.com/makingmedicinepod/ https://www.linkedin.com/showcase/making-medicine-podcast/about/?viewAsMember=true
Timestamps: 0:00 Disclaimer 0:23 Welcome & agenda 0:47 Shutdown Day 15: CDC RIF confusion 2:29 Court injunction + earlier HHS/FDA/NIH cuts 2:49 Cell therapy pullbacks (Novo, Takeda) 3:58 Investment slump in cell & gene therapy 5:21 Policy clarity, China context & hope 6:00 AstraZeneca White House MFN deal vs Pfizer 8:07 NDAA intro & Biosecure refresher 9:40 Interview: What is Biosecure? (John Guy) 12:19 Biosecure 2.0 details: DOD 1260H list, OMB review & due process 14:43 NDAA path, DoD Biotech Office, workforce & wrap
DISCLAIMER: We’re reporting on the headlines, not making medical recommendations. For personal health questions, always consult a doctor.
Making Medicine
There's a scientific breakthrough in your medicine cabinet. But how did it get there?
At a time when medicines are helping us all live longer and healthier lives, this podcast will explore where these taken-for-granted miracles come from, how many of them almost never happened, where the life science ecosystem is taking us next, and most importantly, what it means for patients.
From chance meetings that led to new ideas, to risky investments that never pay off, hear from the people behind today's and tomorrow's treatments, vaccines, technologies, devices, and yes, cures.
In this golden age of health discovery and innovation fueled by record breaking investment in the life sciences, we'll bring guests who really understand what it means to be Making Medicine.
